There are 360 resources available
61MO - IMscin001 (Part 2: Randomized Phase III): Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: MAURICIO BUROTTO PICHUN
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant
Presenter: Luca Mazzarella
Session: Mini Oral session 1
Resources:
Slides
Webcast
Invited Discussant
Presenter: Benjamin Besse
Session: Mini Oral session 1
Resources:
Slides
Webcast
B cell function within tertiary lymphoid structures
Presenter: Tullia Bruno
Session: B cells as a therapeutic opportunity
Resources:
Slides
Webcast
Lessons from neoadjuvant use of immunotherapy before curative-intent surgery
Presenter: Charlotte Lotje Zuur
Session: H&N cancers
Resources:
Slides
Webcast
Lessons from trials of curative-intent (chemo)radiotherapy combined with immunotherapy
Presenter: Maria Teixeira
Session: H&N cancers
Resources:
Slides
Webcast
Tertiary lymphoid structure formation in non-small cell lung cancer
Presenter: Marie-Caroline Dieu-Nosjean
Session: B cells as a therapeutic opportunity
Resources:
Slides
Webcast
Lessons from trials of systemic immunotherapies in relapsed and/or metastatic disease
Presenter: Amanda Psyrri
Session: H&N cancers
Resources:
Slides
Webcast
Antibody responses in the TME
Presenter: Ziv Shulman
Session: B cells as a therapeutic opportunity
Resources:
Slides
Webcast
The role of the tumour microenvironment in oncolytic virotherapy for myeloma
Presenter: Fiona Errington-Mais
Session: Tumour microenvironment
Resources:
Slides
Webcast